

2021 CarePartners of Connecticut HMO Prior Authorization Medical Necessity Guidelines

Effective: December 1, 2021

Updated: December 1, 2021

Control #: H5273_2021_RXOPS193_C



ABILIFY MYCITE

Products Affected

- ABILIFY MYCITE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet the following: 1) have a documented diagnosis of bipolar I disorder, major depressive disorder or schizophrenia 2) the member must have documentation of worsening symptoms due to lack of adherence with oral aripiprazole.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a psychiatrist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AFINITOR

Products Affected

- AFINITOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Afinitor or everolimus: Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Advanced HR+ BC): The member must have a documented diagnosis of Advanced HR+ BC, the member is postmenopausal, concurrently taking exemestane (Aromasin) and has a documented failure of letrozole (Femara) or anastrozole (Arimidex).</p> <p>Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC and the member has a demonstrated disease progression or intolerance following an appropriate trial with Nexavar (sorafenib) or Sutent (sunitinib).</p> <p>Neuroendocrine Tumors (NET): The member must have a documented diagnosis of progressive neuroendocrine tumors of pancreatic origin (pNET) or progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, any of which are unresectable, locally advanced or metastatic.</p> <p>Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC): The member must have a documented presence of TSC and renal angiomyolipoma(s) greater than or equal to 3 cm in longest diameter.</p> <p>Subependymal Giant Cell Astrocytoma (SEGA): The member must have a documented diagnosis of SEGA associated with TSC and the member is not a candidate for surgical resection.</p>
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AFINITOR DISPERZ

Products Affected

- AFINITOR DISPERZ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Partial-onset Seizures Associated with Tuberous Sclerosis Complex (TSC): The member must have a documented diagnosis of partial-onset seizures associated with TSC and is using Afinitor Disperz as an adjunct to other therapies (e.g., anticonvulsants). Subependymal Giant Cell Astrocytoma (SEGA): The member must have a documented diagnosis of SEGA associated with TSC and the member is not a candidate for surgical resection.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AIMOVIG

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Initial: The member must have a documented diagnosis of migraine and the member has had an inadequate response after a 4-week trial of or has a contraindication to antidepressants, antiepileptic drugs (AEDs) or beta blockers. Subsequent: The member has had a clinically significant reduction in migraine days per month from baseline.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 6 months. Subsequent approval: Life of Plan.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ALECENSA

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Anaplastic Lymphoma Kinase positive (ALK-positive), metastatic Non-small Cell Lung Cancer (NSCLC).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ALUNBRIG

Products Affected

- ALUNBRIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ARCALYST

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Cryopyrin-associated periodic syndromes: The member must have a documented diagnosis of a Cryopyrin-Associated Periodic Syndrome, including Familial Cold Autoinflammatory Syndrome, or Muckle-Wells Syndrome. Deficiency of interleukin-1 receptor antagonist: The member must have a documented diagnosis of deficiency of interleukin-1 receptor antagonist and Arcalyst is being used for maintenance of remission in patients weighing 10kg or more. Recurrent Pericarditis (RP): The member must have a documented diagnosis of RP and Arcalyst is being used to reduce the risk of recurrence.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ARMODAFINIL AND MODAFINIL

Products Affected

- *armodafinil*
- *modafinil*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis.
Required Medical Information	The member must have a documented diagnosis of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift-work sleep disorder.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AURYXIA

Products Affected

- AURYXIA

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be approved for the treatment of iron deficiency anemia in patients with CKD not on dialysis.
Required Medical Information	The member must have a documented diagnosis of hyperphosphatemia associated with chronic kidney disease (CKD) and receiving dialysis.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AUSTEDO

Products Affected

- AUSTEDO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chorea Associated with Huntington's Disease: The member must have a documented diagnosis of chorea associated with Huntington's Disease. Tardive Dyskinesia: The member must have a documented diagnosis of Tardive Dyskinesia.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or psychiatrist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

AYVAKIT

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Systemic Mastocytosis (AdvSM): The member must have a documented diagnosis of AdvSM, which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Gastrointestinal Stromal Tumor (GIST): The member must have a documented diagnosis of PDGFRA Exon 18 mutation-positive unresectable or metastatic GIST.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist, immunologist, or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BALVERSA

Products Affected

- BALVERSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and the member progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BENLYSTA

Products Affected

- BENLYSTA

PA Criteria	Criteria Details
Exclusion Criteria	Benlysta (belimumab) will not be approved as monotherapy, for members with severe active lupus nephritis or severe active central nervous system lupus, for members who are autoantibody negative, or in combination with other biologics or intravenous cyclophosphamide.
Required Medical Information	The member must have a documented diagnosis of active, autoantibody-positive (e.g. ANA, anti-ds-DNA, anti-Sm) systemic lupus erythematosus (SLE) and is concurrently taking standard therapy for SLE (e.g., antimalarials, corticosteroids, or immunosuppressives).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BERINERT

Products Affected

- BERINERT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BOSULIF

Products Affected

- BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with a documented resistance or intolerance to prior therapy, including imatinib mesylate (Gleevec) or the member is newly diagnosed with chronic phase Ph+ CML.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BRAFTOVI

Products Affected

- BRAFTOVI

PA Criteria	Criteria Details
Exclusion Criteria	Braftovi is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF CRC.
Required Medical Information	Metastatic Colorectal Cancer: The member must have a documented diagnosis of metastatic colorectal cancer with a BRAF V600E mutation after prior therapy and will be taken combination with cetuximab. Melanoma (unresectable or metastatic): The member must have a documented diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation as detected by an FDA-approved test and will be taken in combination with Mektovi (binimetinib).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BRIVIACT

Products Affected

- BRIVIACT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of partial-onset seizures and has had an insufficient response or intolerance to two or more medications indicated for partial seizures (including but not limited to: Aptiom, felbamate (Felbatol), Fycompa, gabapentin (Fanatrex, Gralise, Neurontin), lamotrigine (Lamictal, Lamictal XR, Lamictal ODT), Lyrica, levetiracetam (Keppra, Keppra XR), oxcarbazepine (Oxtellar XR, Trileptal), tiagabine (Gabitril), topiramate (Topamax, Trokendi XR), Vimpat, and/or zonisamide (Zonegran)).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

BRUKINSA

Products Affected

- BRUKINSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Mantle Cell Lymphoma (MCL) and has received at least one prior therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CABOMETYX

Products Affected

- CABOMETYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Renal Cell Carcinoma (RCC): The member must have a documented diagnosis of advanced renal cell carcinoma (RCC). Differentiated Thyroid Cancer (DTC): The member must have a documented diagnosis of locally advanced or metastatic DTC that has progressed following prior VEGFR-targeted therapy and are radioactive iodine-refractory or ineligible. Hepatocellular Carcinoma (HCC): The member must have a documented diagnosis of HCC and has had a documented failure, contraindication, or intolerance with Nexavar (sorafenib).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CALQUENCE

Products Affected

- CALQUENCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): The member must have a documented diagnosis of CLL or SLL. Mantle Cell Lymphoma (MCL): The member must have a documented diagnosis of MCL and has received at least one prior therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CAPLYTA

Products Affected

- CAPLYTA

PA Criteria	Criteria Details
Exclusion Criteria	Caplyta will not be approved for members with dementia-related psychosis.
Required Medical Information	The member must have a documented diagnosis of schizophrenia.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a psychiatrist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CAPRELSA

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of symptomatic or progressive medullary thyroid cancer with unresectable locally advanced or metastatic disease.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CARBAGLU

Products Affected

- CARBAGLU

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CERDELGA

Products Affected

- CERDELGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Gaucher Disease type 1 and documentation the member is a cytochrome P450 2D6 extensive metabolizer (EMs), intermediate metabolizer (IMs), or poor metabolizer (PMs).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CHOLBAM

Products Affected

- CHOLBAM

PA Criteria	Criteria Details
Exclusion Criteria	Cholbam will not be approved for members with extrahepatic manifestations of either bile acid synthesis disorders due to single enzyme defects (SEDs) or peroxisomal disorders (PDs), including Zellweger spectrum disorders.
Required Medical Information	Bile Acid Synthesis Disorder: The member must have a documented diagnosis of bile acid synthesis disorders due to single enzyme defects (SEDs). Peroxisomal Disorders (PDs): The member must have a documented diagnosis of PDs, including Zellweger spectrum disorders, and exhibit manifestations of hepatic disease, steatorrhea, or complications from decreased fat soluble vitamin absorption and Cholbam is being used as adjunctive therapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CINRYZE

Products Affected

- CINRYZE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

COMETRIQ

Products Affected

- COMETRIQ (100 MG DAILY DOSE)
- COMETRIQ (140 MG DAILY DOSE)
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of progressive, metastatic medullary thyroid cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

COPIKTRA

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): The member must have a documented diagnosis of relapsed or refractory CLL or SLL and has received at least two prior therapies. Follicular lymphoma (FL): The member must have a documented diagnosis of relapsed or refractory FL and has received at least two prior systemic therapies.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

COTELLIC

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	Cotellic is not indicated for treatment of patients with wild-type BRAF melanoma.
Required Medical Information	The member must have a documented diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and is being taken in combination with Zelboraf (vemurafenib).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

CRINONE

Products Affected

- CRINONE

PA Criteria	Criteria Details
Exclusion Criteria	Crinone is excluded as part of an assisted reproductive technology (ART) treatment for infertile women with progesterone deficiency.
Required Medical Information	The member must have a documented diagnosis of secondary amenorrhea.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DAURISMO

Products Affected

- DAURISMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of acute myelogenous leukemia (AML) and Daurismo is being used as first-line therapy in combination with low-dose cytarabine and the member meets one of the following: 1) is 75 years of age or older or 2) has comorbidities that make them ineligible for intensive induction chemotherapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DESOXYN/METHAMPHETAMINE ORAL TABLET

Products Affected

- DESOXYN
- *methamphetamine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	Desoxyn and methamphetamine oral tablets are not covered for narcolepsy and are excluded from coverage for exogenous obesity.
Required Medical Information	The member must have a documented diagnosis of ADHD.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DIACOMIT

Products Affected

- DIACOMIT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of seizures associated with Dravet syndrome and is concurrently taking clobazam.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DICLOFENAC EPOLAMINE PATCH

Products Affected

- *diclofenac epolamine*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of acute pain due to one of the following: minor strain, sprain, or contusion.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DIFICID

Products Affected

- DIFICID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Clostridium difficile-associated diarrhea with a treatment failure or inadequate response to metronidazole or vancomycin.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DOPTELET

Products Affected

- DOPTELET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of one of the following: 1) Thrombocytopenia associated with chronic liver disease (CLD) and is scheduled to undergo a procedure 2) Thrombocytopenia with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DROXIDOPA

Products Affected

- *droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of neurogenic orthostatic hypotension (NOH).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

DUPIXENT

Products Affected

- DUPIXENT

PA Criteria	Criteria Details
Exclusion Criteria	Dupixent will not be approved for the relief of acute bronchospasm or status asthmaticus.
Required Medical Information	Atopic Dermatitis: The member must have a documented diagnosis of moderate-to-severe atopic dermatitis and an inadequate treatment response, intolerance, or contraindication to a high potency topical corticosteroid or a topical calcineurin inhibitor (i.e. tacrolimus, pimecrolimus). Asthma: The member must have a documented diagnosis of moderate-to- severe asthma with an eosinophilic phenotype or is dependent on oral corticosteroids and documentation that underlying conditions or triggers for asthma or pulmonary disease are being maximally managed. Rhinosinusitis (chronic) with nasal polyposis: The member must have a documented diagnosis of chronic rhinosinusitis with nasal polyposis (CRSwNP) and is inadequately controlled on current treatment alone.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist, dermatologist, immunologist, otolaryngologist or pulmonologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EGRIFTA

Products Affected

- EGRIFTA SV

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of HIV-associated lipodystrophy with excess abdominal fat.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EMFLAZA

Products Affected

- EMFLAZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Duchenne muscular dystrophy (DMD).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or a provider who specializes in the treatment of DMD.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EMGALITY

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Initial Approval: The member must have a documented diagnosis of one of the following: 1) Migraine and the member has had an inadequate response, contraindication, or inability to tolerate an appropriate trial after 4-weeks with at least one drug from the following classes: antidepressants (including but not limited to: amitriptyline, venlafaxine), antiepileptic drugs (including but not limited to: divalproex sodium, topiramate) or beta blockers (including but not limited to: propranolol, timolol) 2) Episodic Cluster headache. Subsequent Approval: The member has had a clinically significant reduction in migraine days per month or the frequency of weekly cluster headache attacks from baseline.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 6 months. Subsequent Approval: Life of Plan.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ENBREL

Products Affected

- ENBREL MINI MG/ML
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50
- ENBREL SURECLICK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Ankylosing Spondylitis: The member must have a documented diagnosis of active ankylosing spondylitis. Plaque Psoriasis: The member must have a documented diagnosis of moderate-to-severe chronic plaque psoriasis and has failed to respond to or has been unable to tolerate treatment with one of the following medications: cyclosporine, methotrexate, or acitretin (Soriatane). Rheumatoid Arthritis (RA) and Polyarticular Juvenile Idiopathic Arthritis (PJIA): The member must have a documented diagnosis of either disease and has a documented inadequate response after three months at optimal doses or an inability to take methotrexate. Psoriatic Arthritis: The member must have a documented diagnosis of psoriatic arthritis and has had an inadequate response or inability to take methotrexate or sulfasalazine at maximal doses for three months.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ENSPRYNG

Products Affected

- ENSPRYNG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and are anti-aquaporin-4 (AQP4) antibody positive.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or ophthalmologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EPCLUSA

Products Affected

- EPCLUSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist, hepatologist, or an infectious disease specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EPIDIOLEX

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) or tuberous sclerosis complex (TSC).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ERIVEDGE

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic basal cell carcinoma or locally advanced basal cell carcinoma that has recurred following surgery, or the member is not a candidate for surgery or radiation.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ERLEADA

Products Affected

- ERLEADA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of one of the following: 1) non-metastatic, castration-resistant prostate cancer 2) metastatic, castration-sensitive prostate cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ESBRIET

Products Affected

- ESBRIET ORAL CAPSULE
- ESBRIET ORAL TABLET 267 MG, 801 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of idiopathic pulmonary fibrosis (IPF).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a pulmonologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EUCRISA

Products Affected

- EUCRISA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Members 2 years to 17 years of age: The member must have a documented diagnosis of mild-to-moderate atopic dermatitis and an inadequate treatment response, intolerance, or contraindication to BOTH a low potency topical corticosteroid and a topical calcineurin inhibitor (including but not limited to: tacrolimus, pimecrolimus). Members 18 years of age or older: The member must have a documented diagnosis of mild-to-moderate atopic dermatitis and an inadequate treatment response, intolerance, or contraindication to BOTH a high potency topical corticosteroid and a topical calcineurin inhibitor (including but not limited to: tacrolimus, pimecrolimus).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist or pediatrician.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EVENTITY

Products Affected

- EVENTITY

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must be a postmenopausal woman with a documented diagnosis of osteoporosis with high risk of fracture, defined as a history of osteoporotic fracture or multiple risk factors for fracture, and the member has had an inadequate response to or is unable to tolerate therapy with at least one of the traditional osteoporosis treatments [including but not limited to: alendronate (Fosamax), calcitonin (Miacalcin), ibandronate (Boniva), raloxifene (Evista), risedronate (Actonel), zoledronic acid (Reclast)].
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Lifetime coverage duration of Eventity should be limited to 12 monthly doses.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EVEROLIMUS

Products Affected

- *everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (Advanced HR+ BC): The member must have a documented diagnosis of Advanced HR+ BC, the member is postmenopausal, concurrently taking exemestane (Aromasin) and has a documented failure of letrozole (Femara) or anastrozole (Arimidex). Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC and the member has a demonstrated disease progression or intolerance following an appropriate trial with Nexavar (sorafenib) or Sutent (sunitinib). Neuroendocrine Tumors (NET): The member must have a documented diagnosis of progressive neuroendocrine tumors of pancreatic origin (pNET) or progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, any of which are unresectable, locally advanced or metastatic. Renal Angiomyolipoma with Tuberous Sclerosis Complex (TSC): The member must have a documented presence of TSC and renal angiomyolipoma(s) greater than or equal to 3 cm in longest diameter. Subependymal Giant Cell Astrocytoma (SEGA): The member must have a documented diagnosis of SEGA associated with TSC and the member is not a candidate for surgical resection.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

EVRYSDI

Products Affected

- EVRYSDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of spinal muscular atrophy (SMA).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FARYDAK

Products Affected

- FARYDAK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of multiple myeloma and has received at least two prior therapies including Velcade (bortezomib) and an immunomodulatory agent, and Farydak is being used in combination with dexamethasone and Velcade (bortezomib).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FASENRA

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of severe asthma with an eosinophilic phenotype and documentation that underlying conditions or triggers for asthma or pulmonary disease are being maximally managed.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an asthma specialist (e.g., allergist, immunologist, pulmonologist).
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FINTEPLA

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of seizures associated with Dravet syndrome.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FIRDAPSE

Products Affected

- FIRDAPSE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Lambert-Eaton myasthenic syndrome (LEMS).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FORTEO

Products Affected

- FORTEO SUBCUTANEOUS SOLUTION
- FORTEO SUBCUTANEOUS SOLUTION PEN-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	Coverage for Forteo will not be authorized when cumulative use of it and/or other parathyroid hormone analogs is greater than 2 years.
Required Medical Information	The requesting physician must provide documentation that the member is at high risk for fracture and has a T score less than or equal to -2.0 as evidenced via bone density scan or the requesting physician has documented that the member has had one or more osteoporotic fractures. For either condition previously listed, the member must have had an inadequate response to, or is unable to tolerate therapy with at least one of the traditional osteoporosis treatments (including but not limited to: alendronate (Fosamax), calcitonin (Miacalcin), denosumab (Prolia), ibandronate (Boniva), raloxifene (Evista), risedronate (Actonel) or zoledronic acid (Reclast)).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Cumulative lifetime therapy with Forteo should not exceed 2 years.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FOTIVDA

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

FYCOMPA

Products Affected

- FYCOMPA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Partial-onset Seizures: The member must have a documented diagnosis of partial-onset seizures and has had an insufficient response or intolerance to two or more medications indicated for partial seizures (including but not limited to: Aptiom, Briviact, felbamate (Felbatol), gabapentin (Fanatrex, Gralise, Neurontin), lamotrigine (Lamictal, Lamictal XR, Lamictal ODT), Lyrica, levetiracetam (Keppra, Keppra XR, Roweepra), oxcarbazepine (Oxtellar XR, Trileptal), tiagabine (Gabitril), topiramate (Topamax, Trokendi XR), Vimpat, and/or zonisamide (Zonegran)).</p> <p>Primary Generalized Tonic-clonic Seizures: The member must have a documented diagnosis of primary generalized tonic-clonic seizures and has had an insufficient response or intolerance to two or more medications indicated for primary generalized tonic-clonic seizures (including but not limited to: carbamazepine, felbamate, lamotrigine, levetiracetam, phenytoin, topiramate, and valproate)).</p>
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

GALAFOLD

Products Affected

- GALAFOLD

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a cardiologist, nephrologist, or a specialist in metabolic diseases or genetics.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

GATTEX

Products Affected

- GATTEX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Short Bowel Syndrome (SBS) and is dependent on parenteral nutrition.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

GAVRETO

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Non-small Cell Lung Cancer (NSCLC): The member must have a documented diagnosis of metastatic rearranged during transfection (RET) fusion-positive NSCLC. Thyroid Cancer: The member must have both 1) a documented diagnosis of advanced or metastatic medullary thyroid cancer or advanced or metastatic thyroid cancer 2) documentation of RET-mutant or RET fusion-positive cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

GILOTRIF

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of one of the following: 1) Metastatic non-small cell lung cancer (NSCLC) and documented non-resistant epidermal growth factor receptor (EGFR) mutations 2) Metastatic, squamous cell NSCLC and documentation that the disease has progressed following platinum-based chemotherapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

GROWTH HORMONE REPLACEMENT THERAPY

Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK
- HUMATROPE
- NORDITROPIN FLEXPRO
- NUTROPIN AQ NUSPIN 10
- NUTROPIN AQ NUSPIN 20
- NUTROPIN AQ NUSPIN 5
- OMNITROPE
- SAIZEN
- SAIZENPREP
- SEROSTIM
- ZOMACTON
- ZORBTIVE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Pediatric GHD, Initiation: Member must be evaluated and treated by a pediatric endocrinologist, have not attained epiphyseal closure as determined by X-ray, have failed to respond to at least TWO standard GH stimulation test, have documented gender-specific delayed bone age, have the height at initiation of therapy at greater than 2 standard deviations below normal mean for age and sex. Member must have one of the following: Chronic Renal Insufficiency prior to transplantation, Idiopathic Short Stature, Intrauterine Growth Retardation, Non-genetic GHD, Noonan Syndrome, Prader-Willi Syndrome, Short Stature Homeobox-containing gene (SHOX) deficiency, or Turner Syndrome. Pediatric GHD, Continuation: Documentation of the following is required: Medical history as it relates to growth, including any test results and growth chart, continuing care plan and an improvement in the annualized pre-treatment growth rate after the first six (6) months of therapy. Continuation of Therapy after Completion of Linear Growth: Member will be re-evaluated after GH treatments have been stopped for at least three (3) months to determine growth hormone status AND member must have failed to respond to at least one standard GH stimulation test. Acquired GHD: Member must have failed to respond to at least one standard GH stimulation test. AIDS Wasting Syndrome: Documented diagnosis of AIDS AND a weight loss of at least 10% from baseline weight OR a BMI of less than 20. Short Bowel Syndrome: Documented diagnosis of Short Bowel Syndrome from a gastroenterologist AND a documented dependence on IPN for nutritional support.</p>
Age Restrictions	None

PA Criteria	Criteria Details
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All Medically-accepted Indications.
Off Label Uses	

HAEGARDA

Products Affected

- HAEGARDA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

HARVONI

Products Affected

- HARVONI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist, hepatologist, or an infectious disease specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

HETLIOZ

Products Affected

- HETLIOZ
- HETLIOZ LQ

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be authorized for the diagnosis of insomnia.
Required Medical Information	The member must have a documented diagnosis of Smith-Magenis Syndrome (SMS) and be experiencing nighttime sleep disturbances or the member must be completely blind and have a documented diagnosis of non-24-hour sleep-wake disorder (non-24).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist or sleep specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: ANTIPARKINSON AGENTS

Products Affected

- *benztropine mesylate*
- *trihexyphenidyl hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: amantadine, carbidopa/levodopa, tolcapone.
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: CYCLOBENZAPRINE

Products Affected

- *cyclobenzaprine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: acetaminophen, NSAIDs, baclofen or tizanidine.
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: ESTROGEN-CONTAINING PRODUCTS

Products Affected

- COMBIPATCH
- *dotti*
- *estradiol oral*
- *estradiol transdermal*
- FEMHRT
- FEMHRT LOW DOSE
- *fyavolv*
- *jinteli*
- MENEST
- MENOSTAR
- *norethindrone-eth estradiol*
- PREMARIN ORAL
- PREMPHASE
- PREMPRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: alendronate, calcitonin, Forteo, ibandronate, Prolia, raloxifene, risedronate, zoledronic acid (osteoporosis), estradiol vaginal cream, vaginal tab, vaginal ring (menopausal/vaginal symptoms).
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: HYDROXYZINE

Products Affected

- *hydroxyzine hcl*
- *hydroxyzine pamoate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: levocetirizine (pruritus), duloxetine, escitalopram, venlafaxine ER (anxiety), alprazolam, temazepam (sedation).
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: ORAL HYPOGLYCEMICS

Products Affected

- *glyburide*
- *glyburide micronized*
- *glyburide-metformin*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: glipizide, glipizide-metformin, tolazamide, or tolbutamide.
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: PHENOBARBITAL

Products Affected

- *phenobarbital*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: buspirone (sedation), fosphenytoin, carbamazepine, lamotrigine, levetiracetam, topiramate, valproate (seizures)
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: PROMETHAZINE

Products Affected

- *promethazine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: budesonide nasal, desloratadine, fluticasone nasal, flunisolide nasal, levocetirizine, triamcinolone nasal (allergic rhinitis), Anzemet, aprepitant, Cesamet, Emend, granisetron, perphenazine, ondansetron, prochlorperazine, Sancuso (emesis/motion sickness), buspirone (sedation), desloratadine, levocetirizine (urticaria).
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: THIORIDAZINE

Products Affected

- *thioridazine hcl*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: olanzapine, quetiapine, risperidone, ziprasidone.
Indications	All FDA-approved Indications.
Off Label Uses	

HIGH RISK MEDICATION: TRICYCLIC ANTIDEPRESSANTS

Products Affected

- *amitriptyline hcl*
- *clomipramine hcl*
- *imipramine hcl*
- *imipramine pamoate*
- *trimipramine maleate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented inadequate treatment response, intolerance or contraindication to one or more non-High Risk Medication (non-HRM) alternative formulary drug listed in the OTHER CRITERIA field. Please provide the name(s) of the drug(s) to which the member has had an inadequate treatment response, intolerance or contraindication.
Age Restrictions	The Prior Authorization requirement only applies to members 65 years of age or older.
Prescriber Restrictions	None
Coverage Duration	Initial Approval: 1 year. Subsequent Approval: Life of Plan.
Other Criteria	Non-HRM Alternatives include, but are not limited to: citalopram, duloxetine, escitalopram, venlafaxine (depression), fluoxetine, fluvoxamine, paroxetine, sertraline (depression/OCD). Imipramine is covered for the diagnosis of enuresis.
Indications	All FDA-approved Indications.
Off Label Uses	

HUMIRA

Products Affected

- HUMIRA
- HUMIRA PEDIATRIC CROHNS START
- HUMIRA PEN SUBCUTANEOUS PEN-INJECTOR KIT 40 MG/0.4ML, 40 MG/0.8ML, 80 MG/0.8ML
- HUMIRA PEN-CD/UC/HS STARTER
- HUMIRA PEN-PEDIATRIC UC START
- HUMIRA PEN-PS/UV/ADOL HS START
- HUMIRA PEN-PSOR/UVEIT STARTER

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Ankylosing Spondylitis: The member must have a documented diagnosis of active ankylosing spondylitis. Crohn's Disease and Ulcerative Colitis (UC): The member must have a documented diagnosis of either disease and an inadequate response to an appropriate trial with two or more of the following agents: a) Corticosteroids (including but not limited to: methylprednisolone, prednisolone, prednisone). b) 5-Aminosalicylates (including but not limited to: balsalazide (Colazal), Dipentum, mesalamine (Asacol), Pentasa, Rowasa, sulfasalazine (Azulfidine)). c) 6-mercaptopurine (6-MP, Purinethol) or azathioprine. d) Methotrexate OR the member has demonstrated failure or intolerance to infliximab (Remicade). Hidradenitis Suppurativa: The member must have a documented diagnosis of moderate-to-severe hidradenitis suppurativa. Plaque Psoriasis: The member must have a documented diagnosis of moderate-to-severe chronic plaque psoriasis and has failed to respond to or has been unable to tolerate treatment with one of the following medications: cyclosporine, methotrexate, or acitretin (Soriatane). Psoriatic Arthritis: The member must have a documented diagnosis of active psoriatic arthritis and has had an inadequate response or inability to take methotrexate or sulfasalazine at maximal doses for three months. Rheumatoid Arthritis (RA) and Polyarticular Juvenile Idiopathic Arthritis (PJIA): The member must have a documented diagnosis of either disease and has a documented inadequate response after three months at optimal doses or an inability to take methotrexate. Uveitis: The member must have a documented diagnosis of non-infectious intermediate, posterior, and panuveitis.</p>
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist, gastroenterologist, ophthalmologist, or rheumatologist.

PA Criteria	Criteria Details
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

IBRANCE

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must 1) be a man or post-menopausal woman with a documented diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer and Ibrance is being used in combination with an aromatase inhibitor or 2) have a documented diagnosis of HR-positive, HER2- negative advanced or metastatic breast cancer with disease progression following endocrine therapy and documentation Ibrance (palbociclib) will be used in combination with Faslodex (fulvestrant).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ICATIBANT

Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	Icatibant will not be approved for members with acquired angioedema or concurrently taking an angiotensin converting enzyme (ACE) inhibitor.
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema (HAE) with a history of at least one severe attack in the past six months. For HAE Types 1 & 2, the diagnosis must be confirmed by laboratory testing (e.g., low C4 level, reduced C1 esterase inhibitor level or function).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist, hematologist, or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ICLUSIG

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	Iclusig will not be approved for members with newly diagnosed chronic phase CML.
Required Medical Information	Acute Lymphoblastic Leukemia (ALL): The member must be T315I positive or have a documented diagnosis of Philadelphia chromosome-positive ALL (Ph+ALL) for which no other tyrosine kinase inhibitor therapy is indicated. Chronic Myeloid Leukemia (CML): The member must be T315I positive or have a documented diagnosis of chronic phase, accelerated phase, or blast phase CML for which no other tyrosine kinase inhibitor therapy is indicated.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

IDHIFA

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

IMBRUVICA

Products Affected

- IMBRUVICA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Graft versus Host Disease (cGVHD): The member must have a documented diagnosis of cGVHD and has had a documented inadequate response, contraindication, or inability to tolerate an appropriate trial with one or more lines of systemic therapy. Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): The member must have a documented diagnosis of CLL/SLL. Mantle Cell Lymphoma (MCL): The member must have a documented diagnosis of MCL and has received at least one prior therapy. Marginal Zone Lymphoma (MZL): The member must have a documented diagnosis of MZL and has received at least one prior anti-CD20-based therapy. Waldenstrom Macroglobulinemia: The member must have a documented diagnosis of Waldenstrom macroglobulinemia.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist, oncologist, or transplant specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INBRIJA

Products Affected

- INBRIJA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Parkinson's disease with off episodes and the member is being treated with carbidopa/levodopa.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INCRELEX

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	Coverage of Increlex will not be authorized for conditions resulting in secondary forms of IGF-1 deficiency that include, but are not limited to: GH deficiency, malnutrition, hypothyroidism, or chronic steroid therapy.
Required Medical Information	The member must have a documented diagnosis of severe primary IGF-1 deficiency as defined by a height SD score less than or equal to -3.0, a basal IGF-1 SD score less than or equal to -3.0, normal or elevated GH level OR GH gene deletion and has developed neutralizing antibodies to GH. Radiographs documenting open epiphyses are required for members who are Tanner stage III or greater.
Age Restrictions	The member must be 2 to 18 years of age.
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	Initial authorization is for 6 months. Subsequent authorizations are for 1 year.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INGREZZA

Products Affected

- INGREZZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of tardive dyskinesia.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INLYTA

Products Affected

- INLYTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of advanced renal cell carcinoma and one of the following two requirements: 1) The member is using Inlyta as first line treatment in combination with avelumab or pembrolizumab 2) The member is using Inlyta as a single agent and has failed a trial of at least one systemic therapy (including but not limited to Afinitor, Avastin, Nexavar, Sutent, Torisel, Votrient).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INQOVI

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INREBIC

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

INTRAVENOUS IMMUNE GLOBULIN

Products Affected

- BIVIGAM
- FLEBOGAMMA DIF
- GAMMAGARD
- GAMMAGARD S/D LESS IGA
- GAMMAKED
- GAMMAPLEX
- GAMUNEX-C
- OCTAGAM
- PANZYGA
- PRIVIGEN

PA Criteria	Criteria Details
Exclusion Criteria	Coverage not approved for progressive MS
Required Medical Information	<p>Documented diagnosis of one of the following: Primary humoral immunodeficiency (Congenital agammaglobulinemia, Common variable immunodeficiency, Wiskott-Aldrich syndrome, X-linked agammaglobulinemia, or Severe combined immunodeficiency). Recurrent severe infection and documented severe deficiency or absence of IgG subclass. Clinically significant functional deficiency of humoral immunity as evidenced by documented failure to produce antibodies to specific antigens and a history of recurrent infections. Immune thrombocytopenic purpura (ITP) (Acute and Chronic refractory ITP). Chronic Lymphocytic Leukemia with associated hypogammaglobulinemia. Symptomatic Human Immunodeficiency Virus (HIV) in patients less than 13 years of age, who are immunologically abnormal. Bone marrow transplantation. Solid organ transplantation. Kawasaki disease (mucocutaneous lymph node syndrome). Acute and chronic inflammatory demyelinating polyradiculoneuropathy. Guillain-Barre syndrome. Myasthenia gravis. Immune thrombocytopenic purpura in pregnancy. Multifocal motor neuropathy (MMN) and dermatomyositis. Autoimmune mucocutaneous blistering diseases (Pemphigus vulgaris, Bullous pemphigoid, Mucous membrane pemphigoid [a.k.a., cicatricial pemphigoid], or Epidermolysis bullosa Acquisita). Scleromyxedema is covered for patients whose treatment with more traditional measures has failed. Humoral or vascular allograft rejection. Hemolytic anemia. Polymyositis and Dermatomyositis. Sensitized renal transplant recipients. Sepsis. Kidney disease. CMV infection. von Willebrand disorder. Uveitis. Toxic shock syndrome. RSV infection. HIV-associated thrombocytopenia and treatment of post-transfusion Purpura. Chronic inflammatory demyelinating polyneuropathy. Hepatitis A, Measles (Rubeola). Rubella. Varicella in immunosuppressed patients when varicella zoster immunoglobulin is not available.</p>
Age Restrictions	None

PA Criteria	Criteria Details
Prescriber Restrictions	None
Coverage Duration	Initial authorization is for 6 months.
Other Criteria	None
Indications	All Medically-accepted Indications.
Off Label Uses	

IRESSA

Products Affected

- IRESSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic non-small cell lung cancer (NSCLC) in tumors that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ISTURISA

Products Affected

- ISTURISA ORAL TABLET 1 MG, 10 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Cushing's disease and pituitary surgery is not an option or has not been curative.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

JAKAFI

Products Affected

- JAKAFI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Graft-versus-host Disease (GVHD): The member must have a documented diagnosis of chronic GVHD after failure of one or two lines of systemic therapy. Myelofibrosis: The member must have a documented diagnosis of intermediate or high-risk myelofibrosis. Polycythemia Vera: The member must have a documented diagnosis of polycythemia vera with an inadequate response, contraindication, or inability to tolerate hydroxyurea. Steroid-Refractory Acute Graft-versus-host Disease (GVHD): The member must have a document diagnosis of steroid-refractory acute GVHD.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Initial authorization is for 6 months. Subsequent authorization is for Life of Plan.
Other Criteria	For Myelofibrosis: Subsequent authorization requires documentation of spleen size reduction or symptomatic improvement.
Indications	All FDA-approved Indications.
Off Label Uses	

JUXTAPID

Products Affected

- JUXTAPID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must 1) have a documented diagnosis of homozygous familial hypercholesterolemia (HoFH) based on one of the following tests: a) LDLR DNA Sequence Analysis. b) LDLR Deletion/Duplication Analysis for large gene rearrangement testing (only if the Sequence Analysis is negative). c) APOB and PCSK9 testing if both of the above tests are negative but a strong clinical picture exists and 2) be concurrently taking lipid-lowering medications or has a documented contraindication to lipid-lowering medications and has had a documented inadequate response to an appropriate trial with or a contraindication to a PCSK9 Inhibitor.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KALYDECO

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	Kalydeco is not effective in patients with cystic fibrosis who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Required Medical Information	The member must have a documented diagnosis of cystic fibrosis (CF) and have one mutation in the CFTR gene that is responsive to Kalydeco based on clinical and/or in vitro assay data. If the patient's genotype is unknown, an FDA-cleared cystic fibrosis mutation test should be used to detect the presence of a CFTR mutation followed by verification with bidirectional sequencing when recommended by the mutation test instructions for use.
Age Restrictions	Granules: The member must be 4 months to 5 years of age.
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KERENDIA

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of chronic kidney disease associated with type 2 diabetes.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KESIMPTA

Products Affected

- KESIMPTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KEVEYIS

Products Affected

- KEVEYIS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KINERET

Products Affected

- KINERET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Deficiency of Interleukin-1 Receptor Antagonist (DIRA): The member must have a documented diagnosis of DIRA. Neonatal-Onset Multisystem Inflammatory Disease (NOMID): The member must have a documented diagnosis of NOMID. Rheumatoid Arthritis (RA): The member must have a documented diagnosis of moderately-to-severely active RA and has documented inadequate response after three months at optimal doses or an inability to take methotrexate.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a pediatrician or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KISQALI

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)
- KISQALI FEMARA(200 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Premenopausal or Perimenopausal Women: The member must have a documented diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer and Kisqali is being used in combination with an aromatase inhibitor as initial endocrine-based therapy. Postmenopausal Women: The member must have a documented diagnosis of HR-positive, HER2-negative advanced or metastatic breast cancer and Kisqali is being used in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or Kisqali is being used in combination with fulvestrant following disease progression on endocrine therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KLISYRI

Products Affected

- KLISYRI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of actinic keratosis of the face or scalp.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KORLYM

Products Affected

- KORLYM

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hyperglycemia secondary to hypercortisolism with endogenous Cushing's syndrome and type 2 diabetes mellitus OR glucose intolerance AND has failed surgery OR is not a candidate for surgery.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KOSELUGO

Products Affected

- KOSELUGO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Neurofibromatosis type 1 and have symptomatic, inoperable plexiform neurofibromas.
Age Restrictions	The member must be 2 to 17 years of age.
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

KUVAN

Products Affected

- KUVAN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a specialist in metabolic diseases or a geneticist.
Coverage Duration	Initial authorization is for 8 weeks. Subsequent authorization is for Life of Plan.
Other Criteria	Coverage may be authorized for continuing therapy if the member has demonstrated at least a 30% reduction in phenylalanine levels compared to baseline.
Indications	All FDA-approved Indications.
Off Label Uses	

LAPATINIB

Products Affected

- *lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2) overexpressing advanced or metastatic breast cancer, the member must meet ALL of the following criteria: 1) Documented diagnosis of HER2 overexpressing advanced or metastatic breast cancer. 2) The member has failed prior therapy with an anthracycline and a taxane chemotherapeutic agent. 3) The member has failed prior therapy with Herceptin (trastuzumab). 4) The member is concurrently treated with capecitabine (Xeloda). Hormone Receptor Positive Metastatic Breast Cancer in Post-menopausal Women: The member must have a documented diagnosis of hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and is concurrently being treated with an aromatase inhibitor (including but not limited to: anastrozole, exemestane, or letrozole).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All Medically-accepted Indications.
Off Label Uses	

LENVIMA

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Endometrial Carcinoma: The member must have a documented diagnosis of advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation and it will be used in combination with Keytruda (pembrolizumab). Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC and has had one prior antiangiogenic therapy and is being used in combination with Afinitor (everolimus). Hepatocellular carcinoma (HCC): The member must have a documented diagnosis of unresectable hepatocellular carcinoma. Thyroid Cancer: The member must have a documented diagnosis of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

LIDOCAINE TRANSDERMAL PATCHES

Products Affected

- *lidocaine external patch*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For Postherpetic Neuralgia or Diabetic Neuropathy, the member must have had a failure, adverse reaction, or contraindication to gabapentin. Lidocaine transdermal patches may be approved for members who are not candidates for opioid or other oral pain management therapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	Coverage will be authorized for new members if their pain is currently well-controlled on lidocaine transdermal patches.
Indications	All Medically-accepted Indications.
Off Label Uses	

LONSURF

Products Affected

- LONSURF

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Metastatic Colorectal Cancer (mCRC): The member must have a documented diagnosis of mCRC and has been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and if rat sarcoma viral oncogene (RAS) wild-type, an anti-epidermal growth factor receptor (EGFR) therapy. Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: The member must have a documented diagnosis of metastatic gastric or gastroesophageal junction adenocarcinoma and has been previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

LORBRENA

Products Affected

- LORBRENA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and has demonstrated disease progression on Xalkori (crizotinib) and at least one other ALK inhibitor for metastatic disease, or the member has progressed on Alecensa (alectinib) or Zykadia (ceritinib) as the first ALK inhibitor therapy for metastatic disease.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

LUMAKRAS

Products Affected

- LUMAKRAS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and has received at least one prior systemic therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

LUPKYNIS

Products Affected

- LUPKYNIS

PA Criteria	Criteria Details
Exclusion Criteria	The requested drug will not be approved in combination with cyclophosphamide.
Required Medical Information	The member must have a documented diagnosis of active lupus nephritis and the requested drug is being used in combination with a background immunosuppressive therapy regimen consisting of mycophenolate mofetil and corticosteroids.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a nephrologist or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

LYNPARZA

Products Affected

- LYNPARZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Breast Cancer: The member has a diagnosis of deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer and has been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. If hormone receptor-positive the member should have prior endocrine therapy or contraindication to or inability to tolerate endocrine therapy. Ovarian Cancer: Lynparza is being used for one of the following 1) Maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy 2) Maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with bevacizumab and the member is in complete or partial response to first-line platinum-based chemotherapy and the member's cancer is associated with homologous recombination deficiency (HRD)-positive status 3) Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and the member is in complete or partial response to platinum-based chemotherapy 4) Treatment of deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer and the member has been treated with 3 or more prior lines of chemotherapy. Pancreatic Cancer: The member has a diagnosis of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma and no disease progression after at least 16 weeks of first-line platinum-based chemotherapy. Prostate Cancer: The member has a documented diagnosis of deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.</p>
Age Restrictions	None

PA Criteria	Criteria Details
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MAVYRET

Products Affected

- MAVYRET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist, hepatologist, or an infectious disease specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MEDICATIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION

Products Affected

- ADEMPAS
- *alyq*
- *ambrisentan*
- *bosentan*
- OPSUMIT
- ORENITRAM
- *sildenafil citrate*
- *tadalafil (pah)*
- TRACLEER
- UPTRAVI ORAL TABLET
- UPTRAVI ORAL TABLET THERAPY PACK
- VENTAVIS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of pulmonary arterial hypertension (WHO group I: see below) as confirmed by right heart catheterization. World Health Organization (WHO) Classification of Pulmonary Hypertension - Group 1: a) Idiopathic PAH (primary pulmonary hypertension). b) Heritable PAH. c) Drug- and toxin-induced PAH. d) PAH associated with other diseases and conditions (APAH), such as: i) Connective tissue diseases ii) HIV infection iii) Portal hypertension iv) Congenital heart disease v) Schistosomiasis vi) Chronic hemolytic anemia. e) Persistent pulmonary hypertension of the newborn OR chronic thromboembolic pulmonary hypertension (CTEPH) (WHO Group 4) AND the pulmonary hypertension has progressed despite surgical treatment and/or maximal medical treatment of the underlying condition AND the medication used for treatment is consistent with its FDA-approved functional class.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a cardiologist or pulmonologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MEKINIST

Products Affected

- MEKINIST

PA Criteria	Criteria Details
Exclusion Criteria	Mekinist will not be approved as a single agent for members who have received prior BRAF-inhibitor therapy.
Required Medical Information	Single Agent: The member must have a documented diagnosis of unresectable or metastatic melanoma with a BRAF V600E. In Combination with Tafenlar: The member must have a documented diagnosis of one of the following: 1) Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. 2) Melanoma with a BRAF V600E or V600K mutation and involvement of lymph node(s) following complete resection. 3) Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. 4) Locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600E mutation with no satisfactory locoregional treatment options.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MEKTOVI

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, and will be taken in combination with Braftovi (encorafenib).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MIGLUSTAT

Products Affected

- *miglustat*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of mild-to-moderate Gaucher disease type 1 and enzyme replacement therapy is not a therapeutic option (e.g. allergy, hypersensitivity, poor venous access).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MISCELLANEOUS INJECTABLES

Products Affected

- ABELCET
- ACTHAR
- *acyclovir sodium*
- AMBISOME
- *amphotericin b*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Diagnosis of an FDA-approved indication not otherwise excluded from Part D.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MULPLETA

Products Affected

- MULPLETA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of thrombocytopenia with chronic liver disease and is scheduled to undergo a procedure.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MYCAPSSA

Products Affected

- MYCAPSSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of acromegaly who have responded to and tolerated treatment with octreotide or lanreotide injections.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MYFEMBREE

Products Affected

- MYFEMBREE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must be premenopausal and have a documented diagnosis of uterine leiomyomas (fibroids) associated with heavy menstrual bleeding.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Coverage of Myfembree is limited to 24 months.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

MYTESI

Products Affected

- MYTESI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of non-infectious diarrhea associated with HIV or AIDS and is currently taking antiretroviral therapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NATPARA

Products Affected

- NATPARA

PA Criteria	Criteria Details
Exclusion Criteria	Natpara will not be approved for members who are well-controlled on calcium supplements and active forms of vitamin D alone, or for members with hypoparathyroidism caused by calcium-sensing receptor mutations or acute postsurgical hypoparathyroidism.
Required Medical Information	The member must have a documented diagnosis of hypocalcemia secondary to hypoparathyroidism. Before starting Natpara, the prescriber must confirm sufficient 25-hydroxyvitamin D stores and that serum calcium is above 7.5 mg/dL.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NAYZILAM

Products Affected

- NAYZILAM

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of a seizure disorder requiring acute treatment.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NERLYNX

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Extended Adjuvant Treatment of Early-stage Breast Cancer: The member must have a documented diagnosis of early stage human epidermal growth receptor type 2 (HER2) overexpressed/amplified breast cancer and has had previous adjuvant treatment with Herceptin-based therapy. Advanced or Metastatic Breast Cancer: The member must have a documented diagnosis of advanced or metastatic HER2-positive breast cancer, is using Nerlynx in combination with capecitabine, and has received two or more prior anti-HER2 based regimens.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NEXAVAR

Products Affected

- NEXAVAR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC. Hepatocellular Carcinoma (HCC): The member must have a documented diagnosis of biopsy-proven, unresectable HCC. Thyroid Carcinoma (TC): The member must have a documented diagnosis of locally recurrent or metastatic, progressive, differentiated TC refractory to radioactive iodine treatment.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a nephrologist, oncologist, or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NEXLETOL

Products Affected

- NEXLETOL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet the following criteria: 1) Member has an elevated LDL-C level while being treated with maximally tolerated statin therapy or has an elevated LDL-C level and a contraindication/intolerance to statin therapy. 2) The member must have a documented diagnosis of one of the following: a) Heterozygous Familial Hypercholesterolemia (HeFH) b) atherosclerotic cardiovascular disease
Age Restrictions	None
Prescriber Restrictions	The medication must be prescribed by or in consultation with a cardiologist, endocrinologist, lipidologist, or neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NEXLIZET

Products Affected

- NEXLIZET

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet the following criteria: 1) Member has an elevated LDL-C level while being treated with maximally tolerated statin therapy or has an elevated LDL-C level and a contraindication/intolerance to statin therapy. 2) The member must have a documented diagnosis of one of the following: a) Heterozygous Familial Hypercholesterolemia (HeFH) b) atherosclerotic cardiovascular disease.
Age Restrictions	None
Prescriber Restrictions	The medication must be prescribed by or in consultation with a cardiologist, endocrinologist, lipidologist, or neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NINLARO

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of multiple myeloma and Ninlaro is being used in combination with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NITISINONE

Products Affected

- *nitisinone*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hereditary tyrosinemia type-1 (HT-1).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NITYR

Products Affected

- NITYR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hereditary tyrosinemia Type-1 (HT-1).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NORTHERA

Products Affected

- NORTHERA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of neurogenic orthostatic hypotension (NOH).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NOURIANZ

Products Affected

- NOURIANZ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Parkinson's disease and Nourianz is being used as adjunctive treatment to levodopa/carbidopa in those experiencing "off" episodes.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NUBEQA

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of non-metastatic castration-resistant prostate cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NUCALA

Products Affected

- NUCALA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Severe Asthma with an Eosinophilic Phenotype: The member must have a documented diagnosis of severe asthma with an eosinophilic phenotype and documentation that underlying conditions or triggers for asthma or pulmonary disease are being maximally managed. Eosinophilic granulomatosis with polyangiitis: The member must have a documented diagnosis of eosinophilic granulomatosis with polyangiitis and has had an inadequate response to an appropriate trial with at least one of the following immunosuppressants: azathioprine, cyclophosphamide, or methotrexate. Hypereosinophilic Syndrome (HES): The member must have a documented diagnosis of HES for at least 6 months without an identifiable non-hematologic secondary cause.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an asthma specialist (e.g., allergist, immunologist, pulmonologist), hematologist, or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NUEDEXTA

Products Affected

- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	Nuedexta will not be approved for management of heroin detoxification or neuropathic pain.
Required Medical Information	The member must have a documented diagnosis of pseudobulbar affect (PBA).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Coverage duration is limited to 1 year.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

NUPLAZID

Products Affected

- NUPLAZID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Parkinson's disease and have hallucinations and delusions associated with Parkinson's disease psychosis.
Age Restrictions	None
Prescriber Restrictions	The medication must be prescribed by or in consultation with a neurologist or psychiatrist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

OCALIVA

Products Affected

- OCALIVA

PA Criteria	Criteria Details
Exclusion Criteria	Ocaliva will not be authorized for the treatment of non-alcoholic steatohepatitis.
Required Medical Information	The member must have a documented diagnosis of primary biliary cholangitis (PBC) and Ocaliva is being used in combination with ursodiol if the member has had an inadequate response to treatment with ursodiol alone. Ocaliva may be approved as monotherapy if the member is unable to tolerate ursodiol.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ODOMZO

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of locally advanced basal cell carcinoma and one of the following: 1) Documentation of disease recurrence following surgery or radiation therapy or 2) Documentation that the member is not a candidate for surgery or radiation therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

OFEV

Products Affected

- OFEV

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of one of the following: 1) idiopathic pulmonary fibrosis (IPF) 2) systemic sclerosis-associated interstitial lung disease (SSc-ILD) or 3) chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a pulmonologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ONGENTYS

Products Affected

- ONGENTYS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Parkinson's Disease and has had a documented failure, contraindication, or intolerance to entacapone.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ONUREG

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of acute myeloid leukemia and has achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORALAIR

Products Affected

- ORALAIR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have documentation of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the five grass species contained in this product.
Age Restrictions	The member must be 5 to 65 years of age.
Prescriber Restrictions	The medication must be prescribed by or in consultation with an allergist, immunologist, or pulmonologist.
Coverage Duration	Coverage duration is limited to 1 year.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORFADIN

Products Affected

- ORFADIN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hereditary tyrosinemia type-1 (HT-1).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORGOVYX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of advanced prostate cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORIAHNN

Products Affected

- ORIAHNN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must be premenopausal and have a documented diagnosis of uterine leiomyomas (fibroids) associated with heavy menstrual bleeding.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORILISSA

Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of endometriosis with moderate-to-severe pain.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORKAMBI

Products Affected

- ORKAMBI ORAL PACKET
- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	Orkambi will not be covered for individuals that are not homozygous for the F508del mutation.
Required Medical Information	The member must have a documented diagnosis of cystic fibrosis (CF) and have documentation that the member has the F508del mutation on both alleles of the CFTR gene.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ORLADEYO

Products Affected

- ORLADEYO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

OXERVATE

Products Affected

- OXERVATE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of neurotrophic keratitis.
Age Restrictions	None
Prescriber Restrictions	The medication must be prescribed by or in consultation with an ophthalmologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PALYNZIQ

Products Affected

- PALYNZIQ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of phenylketonuria (PKU) and has uncontrolled blood phenylalanine concentrations greater than 600 micromol per liter on existing management.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a specialist in metabolic diseases or a geneticist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PEMAZYRE

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of unresectable, locally advanced or metastatic Cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and has been previously treated.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet the following criteria: 1) The member must be a man or postmenopausal woman. 2) The member must have a documented diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer. 3) The member has progressed on or after an endocrine-based regimen. 4) Piqray is being used in combination with fulvestrant.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

POMALYST

Products Affected

- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Kaposi Sarcoma: The member must have a documented diagnosis Kaposi sarcoma (KS) or AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). Multiple Myeloma: The member must have a documented diagnosis of multiple myeloma and has received at least two prior therapies including Revlimid (lenalidomide) and a proteasome inhibitor (including but not limited to: Kyprolis, Ninlaro, or Velcade) and has demonstrated disease progression on or within 60 days of completion of the last therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PRALUENT

Products Affected

- PRALUENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet the following criteria: 1) Documented value and date of baseline LDL cholesterol. 2) Documented lipid-lowering treatments and responses. 3) Member has an elevated LDL-C level while being treated with a high-potency statin (see Other Criteria) or has an elevated LDL-C level and a contraindication/intolerance to statin therapy. 4) The member must have a documented diagnosis of one of the following: a) Primary hyperlipidemia including Heterozygous Familial Hypercholesterolemia (HeFH) as confirmed by a genetic test or Meets Simon-Broome or WHO/Dutch Lipid Clinic Network Criteria (see Other Criteria). b) Cardiovascular disease.
Age Restrictions	None
Prescriber Restrictions	The medication must be prescribed by or in consultation with a cardiologist, endocrinologist, lipidologist, or neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	High-potency statin treatment: atorvastatin greater than or equal to 40 mg or rosuvastatin greater than or equal to 20 mg daily. Simon-Broome Diagnostic Criteria for definite FH: Total cholesterol greater than 290 mg/dL or LDL-C greater than 190 mg/dL and tendon xanthomas in the patient, first (parent, sibling or child) or second degree relative (grandparent, uncle or aunt). Dutch Lipid Clinical Network Criteria for definite FH: Total score greater than 8 points.
Indications	All FDA-approved Indications.
Off Label Uses	

PREVYMIS

Products Affected

- PREVYMIS

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have documentation of having had, or is scheduled to receive, an allogeneic hematopoietic stem cell transplant (HSCT) and the member is at risk for cytomegalovirus (CMV) infection.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PROLIA

Products Affected

- PROLIA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Coverage of Prolia (denosumab) for the treatment of osteoporosis in men and postmenopausal women may be authorized when the following criteria are met: 1) The member is at high risk of fracture defined as a history of osteoporotic fracture or multiple risk factors for fracture and a T score less than or equal to -2.0 as evidenced via bone density scan or 2) the member has had an inadequate response to, or is unable to tolerate therapy with at least one of the traditional osteoporosis treatments [including but not limited to: alendronate (Fosamax), calcitonin (Miacalcin), ibandronate (Boniva), raloxifene (Evista), risedronate (Actonel), zoledronic acid (Reclast)] or 3) the member is a female at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and is using Prolia (denosumab) as a treatment to increase bone mass. Coverage of Prolia may also be authorized for 1) men at high risk of fracture who are receiving androgen deprivation therapy for non-metastatic prostate cancer or 2) treatment for glucocorticoid-induced osteoporosis in men and women at high risk for fracture.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

PROMACTA

Products Affected

- PROMACTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Immune (idiopathic) Thrombocytopenic Purpura (ITP): The member must have a documented diagnosis of Chronic ITP and has had an insufficient response or intolerance to corticosteroids, immunoglobulins, or splenectomy. Severe Aplastic Anemia: 1) The member must have a documented diagnosis of severe aplastic anemia and 2) will be taken in combination with, or in those who have had an insufficient response with, standard immunosuppressive therapy. Thrombocytopenia with Chronic Hepatitis C: The member must have a documented diagnosis of thrombocytopenia with chronic hepatitis C infection.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

QINLOCK

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RAVICTI

Products Affected

- RAVICTI

PA Criteria	Criteria Details
Exclusion Criteria	Ravicti will not be approved for members with acute hyperammonemia.
Required Medical Information	The member must have a documented diagnosis of a urea cycle disorder.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

REMICADE

Products Affected

- REMICADE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Ankylosing Spondylitis: The member must have a documented diagnosis of active ankylosing spondylitis. Crohn's Disease, Pediatric Ulcerative Colitis, or Ulcerative Colitis (UC): The member must have a documented diagnosis of one of the aforementioned diseases and an inadequate response to an appropriate trial with two or more of the following agents: a) Corticosteroids (including but not limited to: methylprednisolone, prednisolone, prednisone). b) 5-Aminosalicylates (including but not limited to: balsalazide (Colazal), Dipentum, mesalamine (Asacol), Pentasa, Rowasa, sulfasalazine (Azulfidine)). c) 6-mercaptopurine (6-MP, Purinethol) or azathioprine. d) Methotrexate. Plaque Psoriasis: The member must have a documented diagnosis of severe chronic plaque psoriasis and has failed to respond to or has been unable to tolerate treatment with one of the following medications: cyclosporine, methotrexate, or acitretin (Soriatane). Psoriatic Arthritis: The member must have a documented diagnosis of psoriatic arthritis and has had an inadequate response or inability to take methotrexate or sulfasalazine at maximal doses for three months. Rheumatoid Arthritis (RA): The member must have a documented diagnosis of RA and has documented inadequate response after three months at optimal doses or an inability to take methotrexate.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	

RETEVMO

Products Affected

- RETEVMO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Non-Small Cell Lung Cancer: The member must have a documented diagnosis of metastatic RET fusion-positive non-small cell lung cancer (NSCLC). RET-mutant Medullary Thyroid Cancer: The member must have a documented diagnosis of advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. RET Fusion-Positive Thyroid Cancer: The member must have a documented diagnosis of advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be on oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RETINOIDS FOR THE TOPICAL TREATMENT OF ACNE VULGARIS AND PSORIASIS

Products Affected

- *adapalene*
- *adapalene-benzoyl peroxide*
- ATRALIN
- *avita*
- FABIOR
- RETIN-A
- RETIN-A MICRO
- RETIN-A MICRO PUMP
- *tazarotene*
- TAZORAC
- *tretinoin external*
- *tretinoin microsphere*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage of topical acne products will not be authorized for cosmetic purposes.
Required Medical Information	For all retinoids, the member must have a documented diagnosis of acne vulgaris, comedones (white heads), or actinic keratosis. Tazorac or tazarotene may also be covered if the member has a physician-documented diagnosis of plaque psoriasis or documented diagnosis of skin cancer provided effective treatment with Tazorac or tazarotene is recognized for treatment of such indication in one of the standard reference compendia, or in the medical literature.
Age Restrictions	This criterion only applies to members age 26 or older. Authorization is not required for members 25 years of age or younger.
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All Medically-accepted Indications.
Off Label Uses	

REVLIMID

Products Affected

- REVLIMID

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Follicular Lymphoma (FL): The member must have a documented diagnosis of previously treated follicular lymphoma and Revlimid is being used in combination with a rituximab product. Mantle Cell Lymphoma (MCL): The member must have a documented diagnosis of MCL and the member's disease has relapsed or progressed after two prior therapies, one of which included Velcade (bortezomib). Marginal Zone Lymphoma (MZL): The member must have a documented diagnosis of previously treated marginal zone lymphoma and Revlimid is being used in combination with a rituximab product. Multiple Myeloma: The member must have a documented diagnosis of multiple myeloma and Revlimid is being used in combination with dexamethasone or as maintenance therapy in a member following autologous hematopoietic stem cell transplantation. Myelodysplastic Syndrome (MDS): The member must have a documented diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with the 5q-deletion cytogenetic abnormality.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

REZUROCK

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of chronic graft-versus-host disease and has a failure, contraindication, or intolerance to at least two prior lines of systemic therapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RINVOQ

Products Affected

- RINVOQ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Rheumatoid Arthritis who have had an inadequate response after three months at optimal doses or intolerance to methotrexate.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ROZLYTREK

Products Affected

- ROZLYTREK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Non-small Cell Lung Cancer (NSCLC): The member must have a documented diagnosis of metastatic NSCLC with ROS1-positive tumors. Solid Tumors: The member must have a documented diagnosis of solid tumors that 1) have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, 2) are metastatic or where surgical resection is likely to result in severe morbidity, and 3) have progressed following treatment or have no satisfactory alternative therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RUBRACA

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	Rubraca will not be approved for concurrent use with other chemotherapy agents.
Required Medical Information	Ovarian Cancer: The member must have a documented diagnosis of deleterious germline and/or somatic BRCA mutation associated epithelial ovarian, fallopian tube, or primary peritoneal cancer and has been treated with two or more prior lines of chemotherapy. Recurrent Ovarian Cancer (maintenance): The member must have a documented diagnosis of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and is in a complete or partial response to platinum-based chemotherapy. Prostate Cancer: The member must have a documented diagnosis of deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor directed therapy and a taxane-based chemotherapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RUZURGI

Products Affected

- RUZURGI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Lambert-Eaton myasthenic syndrome (LEMS).
Age Restrictions	The member must be 6 years to less than 17 years of age.
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

RYDAPT

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	Rydapt will not be approved as single-agent induction therapy for the treatment of patients with AML.
Required Medical Information	Acute Myeloid Leukemia (AML): The member must have a documented diagnosis of AML that is FLT3 mutation-positive and Rydapt is being used as first-line therapy in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. Mast Cell Leukemia (MCL): The member must have a documented diagnosis of MCL. Systemic Mastocytosis: The member must have a documented diagnosis of aggressive systemic mastocytosis (ASM) or systemic mastocytosis with associated hematological neoplasm (SM-AHN).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SAPROPTERIN

Products Affected

- *sapropterin dihydrochloride*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a specialist in metabolic diseases or a geneticist.
Coverage Duration	Initial authorization is for 8 weeks. Subsequent authorization is for Life of Plan.
Other Criteria	Coverage may be authorized for continuing therapy if the member has demonstrated at least a 30% reduction in phenylalanine levels compared to baseline.
Indications	All FDA-approved Indications.
Off Label Uses	

SIGNIFOR

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Cushing's disease and pituitary surgery is not an option or has not been curative.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SIRTURO

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of pulmonary multi-drug resistant tuberculosis (MDR-TB) and Sirturo is being used in combination with at least three other drugs to which the member's MDR-TB isolate has been shown to be susceptible in vitro. If in vitro testing results are unavailable, treatment may be initiated with Sirturo in combination with at least four other drugs to which the member's MDR-TB isolate is likely to be susceptible.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SKYRIZI

Products Affected

- SKYRIZI
- SKYRIZI (150 MG DOSE)
- SKYRIZI PEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of moderate-to-severe chronic plaque psoriasis and has failed to respond to, or has been unable to tolerate treatment with one (1) of the following medications: cyclosporine, methotrexate, or acitretin (Soriatane).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SOMAVERT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of acromegaly and has had a failure of, or is unable to tolerate, a treatment regimen that includes octreotide, and the member is not a candidate for or has had an inadequate response to surgery and/or radiation.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an endocrinologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SPRYCEL

Products Affected

- SPRYCEL ORAL TABLET 100 MG, 140 MG, 20 MG, 50 MG, 70 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Myeloid Leukemia (CML): 1) The member must have a documented diagnosis of Philadelphia chromosome-positive (Ph+) CML in chronic phase or 2) The member has a documented diagnosis of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML and documented resistance or intolerance to prior therapy, including imatinib mesylate (Gleevec). Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL): The member must have a documented diagnosis of Ph+ALL and documented resistance or intolerance to prior therapy, including imatinib mesylate (Gleevec). For Pediatric Members: The member must have a documented diagnosis of Ph+CML in chronic phase or the member has Ph+ALL and Sprycel is being used in combination with chemotherapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

STELARA

Products Affected

- STELARA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Crohn's disease: 1) The member must have a documented diagnosis of moderately to severely active Crohn's disease and 2) the member had an inadequate response, intolerance, or contraindication to Humira. Plaque Psoriasis: 1) The member must have a documented diagnosis of moderate to severe plaque psoriasis with at least 5% of body surface area (BSA) affected OR crucial body areas (e.g., feet, hands, face, neck, groin, intertriginous areas) are affected at the time of diagnosis, AND 2) the member had an inadequate response, intolerance, or contraindication to Enbrel or Humira. Psoriatic Arthritis: 1) The member must have a documented diagnosis of active psoriatic arthritis (PsA) and 2) the member had an inadequate response, intolerance, or contraindication to Enbrel, Humira or Xeljanz/Xeljanz XR. Ulcerative Colitis (UC): The member must have a documented diagnosis of moderate-to-severely active UC and has had an inadequate response to an appropriate trial with two or more of the following agents: a) Corticosteroids (including but not limited to: methylprednisolone, prednisolone, prednisone). b) 5-Aminosalicylates (including but not limited to: balsalazide (Colazal), Dipentum, mesalamine (Asacol), Pentasa, Rowasa, sulfasalazine (Azulfidine)). c) 6-mercaptopurine (6-MP, Purinethol) or azathioprine. d) methotrexate.</p>
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist, gastroenterologist or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.

PA Criteria	Criteria Details
Off Label Uses	

STIVARGA

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Gastrointestinal Stromal Tumors (GIST): The member must have a documented diagnosis of GIST and documented failure, contraindication, or intolerance to both imatinib mesylate (Gleevec) and Sutent (sunitinib malate). Hepatocellular Carcinoma: The member must have a documented diagnosis of hepatocellular carcinoma and had a documented failure, contraindication, or intolerance to Nexavar (sorafenib). Metastatic Colorectal Cancer (MCC): The member must have a documented diagnosis of MCC and has been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an antivascular endothelial growth factor (VEGF) therapy, and, if RAS wild type, an antiepidermal growth factor receptor (EGFR) therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SUNITINIB

Products Affected

- *sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC. Gastrointestinal Stromal Tumor (GIST): The member must have a documented diagnosis of GIST and has a demonstrated disease progression or intolerance following an appropriate trial with imatinib mesylate (Gleevec). Progressive Neuroendocrine Tumors (pNET): The member must have a documented diagnosis of unresectable, locally advanced, or metastatic pNET located in the pancreas. Recurrent Renal Cell Carcinoma (RCC): The member must have a documented diagnosis of recurrent RCC following nephrectomy and Sunitinib is being used as adjuvant therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SUNOSI

Products Affected

- SUNOSI

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis.
Required Medical Information	The member must have a documented diagnosis of excessive daytime sleepiness associated with either narcolepsy or obstructive sleep apnea (OSA).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SUTENT

Products Affected

- SUTENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC. Gastrointestinal Stromal Tumor (GIST): The member must have a documented diagnosis of GIST and has a demonstrated disease progression or intolerance following an appropriate trial with imatinib mesylate (Gleevec). Progressive Neuroendocrine Tumors (pNET): The member must have a documented diagnosis of unresectable, locally advanced, or metastatic pNET located in the pancreas. Recurrent Renal Cell Carcinoma (RCC): The member must have a documented diagnosis of recurrent RCC following nephrectomy and Sutent is being used as adjuvant therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

SYMDEKO

Products Affected

- SYMDEKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cystic fibrosis (CF), who are homozygous for the F508del mutation or have one mutation in the CFTR gene that is responsive to Symdeko based on clinical and/or in vitro assay data. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bidirectional sequencing when recommended by the mutation test instructions for use.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TABRECTA

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TADALAFIL

Products Affected

- *tadalafil*

PA Criteria	Criteria Details
Exclusion Criteria	Tadalafil is excluded from coverage for the treatment of Erectile Dysfunction.
Required Medical Information	The member must have a documented diagnosis or signs and symptoms of Benign Prostatic Hyperplasia (BPH) and has had a documented failure, adverse reaction, or contraindication to a 30-day trial of at least two of the following medications: alfuzosin, doxazosin, dutasteride, dutasteride-tamsulosin, finasteride, tamsulosin, or terazosin.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TAFINLAR

Products Affected

- TAFINLAR

PA Criteria	Criteria Details
Exclusion Criteria	Tafinlar is not indicated for the treatment of patients with wild-type BRAF mutations.
Required Medical Information	Single Agent: The member must have a documented diagnosis of unresectable or metastatic melanoma with a BRAF V600E mutation. In Combination with Mekinist: The member must have a documented diagnosis of one of the following: 1) Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. 2) Melanoma with a BRAF V600E or V600K mutation and involvement of lymph node(s) following complete resection. 3) Metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. 4) Locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600E mutation with no satisfactory locoregional treatment options.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TAGRISSEO

Products Affected

- TAGRISSEO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of 1) metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations OR 2) metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy (including but not limited to: Gilotrif, Iressa, Tarceva) or 3) NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations and Tagrisso is being used as adjuvant therapy after tumor resection.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TAKHZYRO

Products Affected

- TAKHZYRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of Hereditary Angioedema.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist or immunologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TALTZ

Products Affected

- TALTZ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Ankylosing Spondylitis: The member must have a documented diagnosis of active ankylosing spondylitis and has had an inadequate response, contraindication, or inability to tolerate Humira or Enbrel. Plaque Psoriasis: The member must have a documented diagnosis of moderate-to-severe plaque psoriasis and has had an inadequate response, contraindication, or inability to tolerate Humira, Enbrel, or Skyrizi. Psoriatic Arthritis: The member must have a documented diagnosis of active psoriatic arthritis and has had an inadequate response, contraindication, or inability to tolerate Humira, Enbrel, or Xeljanz/Xeljanz XR. Non-radiographic Axial Spondyloarthritis: The member must have a documented diagnosis of active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a dermatologist or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TALZENNA

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TARGRETIN GEL

Products Affected

- TARGRETIN EXTERNAL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cutaneous T-cell lymphoma with refractory or persistent disease after other therapies or with an intolerance to other therapies.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TASIGNA

Products Affected

- TASIGNA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML): The member must have a documented diagnosis of Ph+ CML in chronic phase and Tasigna is being used as initial therapy. Resistant or Intolerant Ph+ CML-CP and CML-AP: The member must have a documented diagnosis of Ph+ CML in chronic phase or accelerated phase and documented resistance or intolerance to prior therapy, including imatinib mesylate (Gleevec).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TAZVERIK

Products Affected

- TAZVERIK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have one of the following requirements: 1) The member must have a documented diagnosis of metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. 2) The member must have a documented diagnosis of relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and has received at least two prior systemic therapies. 3) The member must have a documented diagnosis of relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TEGSEDI

Products Affected

- TEGSEDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TEPMETKO

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TERIPARATIDE

Products Affected

- *teriparatide (recombinant)*

PA Criteria	Criteria Details
Exclusion Criteria	Coverage for teriparatide will not be authorized when cumulative use of it and/or other parathyroid hormone analogs is greater than 2 years.
Required Medical Information	The requesting physician must provide documentation that the member is at high risk for fracture and has a T score less than or equal to -2.0 as evidenced via bone density scan or the requesting physician has documented that the member has had one or more osteoporotic fractures. For either condition previously listed, the member must have had an inadequate response to, or is unable to tolerate therapy with at least one of the traditional osteoporosis treatments (including but not limited to: alendronate (Fosamax), calcitonin (Miacalcin), denosumab (Prolia), ibandronate (Boniva), raloxifene (Evista), risedronate (Actonel) or zoledronic acid (Reclast)).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Cumulative lifetime therapy with teriparatide should not exceed 2 years.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TETRABENAZINE

Products Affected

- *tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of chorea associated with Huntington's Disease.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TIBSOVO

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	<p>Relapsed or Refractory Acute Myeloid Leukemia (AML): The member must have a documented diagnosis of relapsed or refractory AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Acute Myeloid Leukemia (AML): The member must have a documented diagnosis of AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, Tibsovo is being used as first-line therapy, and the member meets one of the following: 1) is 75 years of age or older or 2) has comorbidities that make them ineligible for intensive induction chemotherapy.</p> <p>Cholangiocarcinoma: The member must have a documented diagnosis of locally advanced or metastatic cholangiocarcinoma who have been previously treated.</p>
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL (TIRF)

Products Affected

- ACTIQ
- *fentanyl citrate*
- LAZANDA NASAL SOLUTION 100 MCG/ACT, 400 MCG/ACT
- SUBSYS

PA Criteria	Criteria Details
Exclusion Criteria	The Transmucosal Immediate-Release Fentanyl (TIRF) products will not be covered for any non-cancer pain indication.
Required Medical Information	The Transmucosal Immediate-Release Fentanyl (TIRF) products may be covered for the management of breakthrough pain in adult cancer patients who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Age Restrictions	None.
Prescriber Restrictions	The prescribing physician must be an oncologist or a pain management specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of, but not limited to, morphine oral 60 mg daily or more, fentanyl transdermal 25 mcg/hour or more, oxycodone oral 30 mg daily or more, hydromorphone oral 8 mg daily or more, or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking fentanyl transmucosal.
Indications	All FDA-approved Indications.
Off Label Uses	

TRIKAFTA

Products Affected

- TRIKAFTA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cystic fibrosis (CF) with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TRUSELTIQ

Products Affected

- TRUSELTIQ (100MG DAILY DOSE)
- TRUSELTIQ (125MG DAILY DOSE)
- TRUSELTIQ (50MG DAILY DOSE)
- TRUSELTIQ (75MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TUKYSA

Products Affected

- TUKYSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must 1) have a documented diagnosis of advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting and 2) be taking in combination with trastuzumab and capecitabine.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TURALIO

Products Affected

- TURALIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and the condition is not amenable to improvement with surgery.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TYKERB

Products Affected

- TYKERB

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2) overexpressing advanced or metastatic breast cancer, the member must meet ALL of the following criteria: 1) Documented diagnosis of HER2 overexpressing advanced or metastatic breast cancer. 2) The member has failed prior therapy with an anthracycline and a taxane chemotherapeutic agent. 3) The member has failed prior therapy with Herceptin (trastuzumab). 4) The member is concurrently treated with capecitabine (Xeloda). Hormone Receptor Positive Metastatic Breast Cancer in Post-menopausal Women: The member must have a documented diagnosis of hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and is concurrently being treated with an aromatase inhibitor (including but not limited to: anastrozole, exemestane, or letrozole).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

TYMLOS

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	Coverage for Tymlos will not be authorized when cumulative use of it and/or other parathyroid hormone analogs is greater than 2 years.
Required Medical Information	The requesting physician must provide documentation that the member is at high risk for fracture and has a T score less than or equal to -2.0 as evidenced via bone density scan or the requesting physician has documented that the member has had one or more osteoporotic fractures. For either condition previously listed, the member must have had an inadequate response to, or is unable to tolerate therapy with at least one of the traditional osteoporosis treatments: alendronate (Fosamax), calcitonin (Miacalcin), denosumab (Prolia), ibandronate (Boniva), raloxifene (Evista), risedronate (Actonel) or zoledronic acid (Reclast).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	Coverage of Tymlos is limited to 24 months.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

UKONIQ

Products Affected

- UKONIQ

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of 1) relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen or 2) relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VALTOCO

Products Affected

- VALTOCO 10 MG DOSE
- VALTOCO 15 MG DOSE
- VALTOCO 20 MG DOSE
- VALTOCO 5 MG DOSE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of a seizure disorder requiring acute treatment.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VENCLEXTA

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Acute Myeloid Leukemia (AML): The member must have a documented diagnosis of AML and Venclexta is being used as first-line therapy in combination with azacitidine, decitabine, or low-dose cytarabine and the member meets one of the following: 1) is 75 years of age or older or 2) has comorbidities that make them ineligible for intensive induction chemotherapy. Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): The member must have a documented diagnosis of CLL/SLL.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VERZENIO

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	For Monotherapy: The member must have a documented diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy. For Combination Therapy with Faslodex (fulvestrant): The member must have a documented diagnosis of HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. For Combination Therapy with an Aromatase Inhibitor: The member must be postmenopausal with a documented diagnosis of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VITRAKVI

Products Affected

- VITRAKVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic or surgically unresectable neurotrophic receptor tyrosine kinase (NTRK) gene fusion-positive solid tumors with no known acquired resistance mutation and with no satisfactory alternative treatments or the member has progressed following treatment.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VIZIMPRO

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic non-small cell lung cancer (NSCLC) in tumors that have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VOSEVI

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Criteria will be applied consistent with current AASLD-IDSA guidance.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist, hepatologist, or an infectious disease specialist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VOTRIENT

Products Affected

- VOTRIENT

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Advanced Renal Cell Carcinoma (ARCC): The member must have a documented diagnosis of ARCC. Advanced Soft Tissue Sarcoma (ASTS): The member must have a documented diagnosis of ASTS and has received prior chemotherapy, including anthracycline treatment, or was unsuited for such therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VYNDAMAX

Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a cardiologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VYNDAQEL

Products Affected

- VYNDAQEL

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a cardiologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

VYVANSE

Products Affected

- VYVANSE

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	ADHD: The member must have a documented diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and has failed or has had an inability to tolerate 2 or more generic medications indicated for ADHD.BED: The member must have a documented diagnosis of Moderate to Severe Binge Eating Disorder (BED).
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

WAKIX

Products Affected

- WAKIX

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis.
Required Medical Information	The member must have a documented diagnosis of either excessive daytime sleepiness (EDS) or cataplexy both of which must also be associated with narcolepsy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

WELIREG

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of von Hippel-Lindau disease and require therapy for associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XALKORI

Products Affected

- XALKORI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of 1) metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or the member has documented ROS1-positive tumors or 2) relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XCOPRI

Products Affected

- XCOPRI
- XCOPRI (250 MG DAILY DOSE)
- XCOPRI (350 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of partial-onset seizures.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a neurologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XELJANZ

Products Affected

- XELJANZ ORAL SOLUTION
- XELJANZ ORAL TABLET
- XELJANZ XR

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): The member must have a documented diagnosis of active pcJIA and has had an inadequate response or inability to take methotrexate at maximal doses for three months. Psoriatic Arthritis: The member must have a documented diagnosis of psoriatic arthritis and has had an inadequate response or inability to take methotrexate or sulfasalazine at maximal doses for three months. Rheumatoid Arthritis (RA): The member must have a documented diagnosis of moderately-to-severely active RA and has a documented inadequate response after three months at optimal doses or an inability to take methotrexate. Ulcerative Colitis (UC): The member must have a documented diagnosis of moderate-to-severely active UC and has had an inadequate response to an appropriate trial with two or more of the following agents: a) Corticosteroids (including but not limited to: methylprednisolone, prednisolone, prednisone). b) 5-Aminosalicylates (including but not limited to: balsalazide (Colazal), Dipentum, mesalamine (Asacol), Pentasa, Rowasa, sulfasalazine (Azulfidine)). c) 6-mercaptopurine (6-MP, Purinethol) or azathioprine. d) methotrexate
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist or rheumatologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XERMELO

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of carcinoid syndrome diarrhea that is inadequately controlled by somastatin analog (SSA) therapy alone and Xermelo is being used in combination with an SSA (e.g. Sandostatin LAR).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a gastroenterologist, hematologist, or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XGEVA

Products Affected

- XGEVA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Coverage for Xgeva (denosumab) may be authorized if one of the following is met: 1) for prevention of skeletal-related events in patients with multiple myeloma or with bone metastases from solid tumors 2) the member is being treated for unresectable giant cell tumor of bone (GCTB) or surgical resection of GCTB is likely to result in severe morbidity 3) for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XIFAXAN 550 MG

Products Affected

- XIFAXAN ORAL TABLET 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	Coverage will not be authorized for treatment of Irritable Bowel Syndrome with constipation (IBS-C).
Required Medical Information	Hepatic Encephalopathy: The member must have a documented diagnosis of hepatic encephalopathy and has had an inadequate response or a contraindication to lactulose. Irritable Bowel Syndrome with Diarrhea (IBS-D): The member must have a documented diagnosis of IBS-D.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	Xifaxan 200 mg tablets do not require authorization.
Indications	All FDA-approved Indications.
Off Label Uses	

XOLAIR

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	Xolair will not be approved for the relief of acute bronchospasm or status asthmaticus.
Required Medical Information	Asthma: The member must 1) have a documented diagnosis of moderate-to-severe persistent asthma 2) has had a failure of a treatment regimen that included two or more of the following medications: inhaled corticosteroids, oral corticosteroids, leukotriene modifiers and inhaled long-acting bronchodilators, or is unable to tolerate these medications. 3) shows a definitive sensitivity on allergy testing to one or more perennial allergens and 4) The member has a pre-treatment serum IgE level equal to or greater than 30 IU/mL and less than or equal to 1,300 IU/mL. CIU: 1) The member has a documented diagnosis of chronic idiopathic urticaria (CIU) and 2) the physician has documented that the member remains symptomatic despite H1 antihistamine treatment. Nasal polyps: The member must have a documented diagnosis of nasal polyps with inadequate response to nasal corticosteroids.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an allergist, dermatologist, immunologist, otolaryngologist or pulmonologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XOSPATA

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XPOVIO

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
- XPOVIO (40 MG ONCE WEEKLY)
- XPOVIO (40 MG TWICE WEEKLY)
- XPOVIO (60 MG ONCE WEEKLY)
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	In combination with dexamethasone: The member must meet ALL of the following criteria: 1) Documented diagnosis of relapsed or refractory multiple myeloma. 2) Has received at least four prior therapies. 3) The member's disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In combination with (Velcade) bortezomib and dexamethasone: The member must have a documented diagnosis of multiple myeloma and has received at least one prior therapy. Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The member must have a documented diagnosis of DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, and has received at least 2 lines of systemic therapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration.
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XTANDI

Products Affected

- XTANDI

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

XURIDEN

Products Affected

- XURIDEN

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of hereditary orotic aciduria.
Age Restrictions	None
Prescriber Restrictions	None
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

YONSA

Products Affected

- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic castration-resistant prostate cancer (mCRPC) and is being used in combination with methylprednisolone.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZEJULA

Products Affected

- ZEJULA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must meet one of the two following requirements: 1) The member must have a documented diagnosis of advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and is experiencing complete or partial response to platinum-based chemotherapy. 2) The member must have a documented diagnosis of advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZELBORAF

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	Zelboraf is not indicated for treatment of patients with wild-type BRAF melanoma.
Required Medical Information	Erdheim-Chester Disease (ECD): The member must have a documented diagnosis of ECD with a BRAF V600 mutation. Unresectable or Metastatic Melanoma: The member must have a documented diagnosis of unresectable or metastatic melanoma that is BRAF V600E mutation-positive.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZOLINZA

Products Affected

- ZOLINZA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of cutaneous T-cell lymphoma (Stage IIB and higher) and progressive, persistent or recurrent disease and documented current or prior treatment or treatment failure with at least two systemic chemotherapeutic agents for cutaneous T-cell lymphoma.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZYDELIG

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	Chronic Lymphocytic Leukemia (CLL): The member must have a documented diagnosis of relapsed CLL and Zydelig is being used in combination with Rituxan (rituximab). Follicular B-cell non-Hodgkin Lymphoma and Small Lymphocytic Lymphoma (SLL): The member must have a documented diagnosis of either disease and documented use of at least two prior systemic therapies.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be a hematologist or oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZYKADIA

Products Affected

- ZYKADIA

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

ZYTIGA

Products Affected

- *abiraterone acetate*

PA Criteria	Criteria Details
Exclusion Criteria	None
Required Medical Information	The member must have a documented diagnosis of metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer and abiraterone is being used in combination with prednisone.
Age Restrictions	None
Prescriber Restrictions	The prescribing physician must be an oncologist or urologist.
Coverage Duration	FDA-approved duration, balance of contract year or clinically appropriate duration
Other Criteria	None
Indications	All FDA-approved Indications.
Off Label Uses	

Index

ABELCET.....	122	CINRYZE.....	27
ABILIFY MYCITE.....	2	<i>clomipramine hcl</i>	78
<i>abiraterone acetate</i>	241	COMBIPATCH.....	72
ACTHAR.....	122	COMETRIQ (100 MG DAILY DOSE).....	28
ACTIQ.....	204	COMETRIQ (140 MG DAILY DOSE).....	28
<i>acyclovir sodium</i>	122	COMETRIQ (60 MG DAILY DOSE).....	28
<i>adapalene</i>	168	COPIKTRA.....	29
<i>adapalene-benzoyl peroxide</i>	168	COTELLIC.....	30
ADEMPAS.....	118	CRINONE.....	31
AFINITOR.....	3	<i>cyclobenzaprine hcl</i>	71
AFINITOR DISPERZ.....	4	DAURISMO.....	32
AIMOVIG.....	5	DESOXYN.....	33
ALECENSA.....	6	DIACOMIT.....	34
ALUNBRIG.....	7	<i>diclofenac epolamine</i>	35
<i>alyq</i>	118	DIFICID.....	36
AMBISOME.....	122	DOPTELET.....	37
<i>ambrisentan</i>	118	<i>dotti</i>	72
<i>amitriptyline hcl</i>	78	<i>droxidopa</i>	38
<i>amphotericin b</i>	122	DUPIXENT.....	39
ARCALYST.....	8	EGRIFTA SV.....	40
<i>armodafinil</i>	9	EMFLAZA.....	41
ATRALIN.....	168	EMGALITY.....	42
AURYXIA.....	10	EMGALITY (300 MG DOSE).....	42
AUSTEDO.....	11	ENBREL MINI.....	43
<i>avita</i>	168	ENBREL SUBCUTANEOUS SOLUTION.....	43
AYVAKIT.....	12	ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 25 MG/0.5ML, 50 MG/ML.....	43
BALVERSA.....	13	ENBREL SUBCUTANEOUS SOLUTION RECONSTITUTED.....	43
BENLYSTA.....	14	ENBREL SURECLICK.....	43
<i>benztropine mesylate</i>	70	ENSPRYNG.....	44
BERINERT.....	15	EPCLUSA.....	45
BIVIGAM.....	92	EPIDIOLEX.....	46
<i>bosentan</i>	118	ERIVEDGE.....	47
BOSULIF ORAL TABLET 100 MG, 400 MG, 500 MG.....	16	ERLEADA.....	48
BRAFTOVI.....	17	ESBRIET ORAL CAPSULE.....	49
BRIVIACT.....	18	ESBRIET ORAL TABLET 267 MG, 801 MG.....	49
BRUKINSA.....	19	<i>estradiol oral</i>	72
CABOMETYX.....	20	<i>estradiol transdermal</i>	72
CALQUENCE.....	21	EUCRISA.....	50
CAPLYTA.....	22	EVENITY.....	51
CAPRELSA ORAL TABLET 100 MG, 300 MG.....	23	<i>everolimus oral tablet 2.5 mg, 5 mg, 7.5 mg</i>	52
CARBAGLU.....	24	EVRYSDI.....	53
CERDELGA.....	25		
CHOLBAM.....	26		

FABIOR.....	168	IBRANCE.....	81
FARYDAK.....	54	<i>icatibant acetate</i>	82
FASENRA.....	55	ICLUSIG.....	83
FASENRA PEN.....	55	IDHIFA.....	84
FEMHRT.....	72	IMBRUVICA.....	85
FEMHRT LOW DOSE.....	72	<i>imipramine hcl</i>	78
<i>fentanyl citrate</i>	204	<i>imipramine pamoate</i>	78
FINTEPLA.....	56	INBRIJA.....	86
FIRDAPSE.....	57	INCRELEX.....	87
FLEBOGAMMA DIF.....	92	INGREZZA.....	88
FORTEO SUBCUTANEOUS SOLUTION.....	58	INLYTA.....	89
FORTEO SUBCUTANEOUS SOLUTION		INQOVI.....	90
PEN-INJECTOR.....	58	INREBIC.....	91
FOTIVDA.....	59	IRESSA.....	94
<i>fyavolv</i>	72	ISTURISA ORAL TABLET 1 MG, 10	
FYCOMPA.....	60	MG, 5 MG.....	95
GALAFOLD.....	61	JAKAFI.....	96
GAMMAGARD.....	92	<i>jinteli</i>	72
GAMMAGARD S/D LESS IGA.....	92	JUXTAPID.....	97
GAMMAKED.....	92	KALYDECO.....	98
GAMMAPLEX.....	92	KERENDIA.....	99
GAMUNEX-C.....	92	KESIMPTA.....	100
GATTEX.....	62	KEVEYIS.....	101
GAVRETO.....	63	KINERET.....	102
GENOTROPIN.....	65	KISQALI (200 MG DOSE).....	103
GENOTROPIN MINIQUICK.....	65	KISQALI (400 MG DOSE).....	103
GILOTRIF.....	64	KISQALI (600 MG DOSE).....	103
<i>glyburide</i>	74	KISQALI FEMARA (400 MG DOSE).....	103
<i>glyburide micronized</i>	74	KISQALI FEMARA (600 MG DOSE).....	103
<i>glyburide-metformin</i>	74	KISQALI FEMARA(200 MG DOSE).....	103
HAEGARDA.....	67	KLISYRI.....	104
HARVONI.....	68	KORLYM.....	105
HETLIOZ.....	69	KOSELUGO.....	106
HETLIOZ LQ.....	69	KUVAN.....	107
HUMATROPE.....	65	<i>lapatinib ditosylate</i>	108
HUMIRA.....	79	LAZANDA NASAL SOLUTION 100	
HUMIRA PEDIATRIC CROHNS START.....	79	MCG/ACT, 400 MCG/ACT.....	204
HUMIRA PEN SUBCUTANEOUS PEN-		LENVIMA (10 MG DAILY DOSE).....	109
INJECTOR KIT 40 MG/0.4ML, 40		LENVIMA (12 MG DAILY DOSE).....	109
MG/0.8ML, 80 MG/0.8ML.....	79	LENVIMA (14 MG DAILY DOSE).....	109
HUMIRA PEN-CD/UC/HS STARTER.....	79	LENVIMA (18 MG DAILY DOSE).....	109
HUMIRA PEN-PEDIATRIC UC START... ..	79	LENVIMA (20 MG DAILY DOSE).....	109
HUMIRA PEN-PS/UV/ADOL HS START.....	79	LENVIMA (24 MG DAILY DOSE).....	109
HUMIRA PEN-PSOR/UEVIT STARTER.. ..	79	LENVIMA (4 MG DAILY DOSE).....	109
<i>hydroxyzine hcl</i>	73	LENVIMA (8 MG DAILY DOSE).....	109
<i>hydroxyzine pamoate</i>	73	<i>lidocaine external patch</i>	110

LONSURF.....	111	ORENITRAM.....	118
LORBRENA.....	112	ORFADIN.....	148
LUMAKRAS.....	113	ORGOVYX.....	149
LUPKYNIS.....	114	ORIAHNN.....	150
LYNPARZA.....	115	ORILISSA ORAL TABLET 150 MG, 200 MG.....	151
MAVYRET.....	117	ORKAMBI ORAL PACKET.....	152
MEKINIST.....	119	ORKAMBI ORAL TABLET.....	152
MEKTOVI.....	120	ORLADEYO.....	153
MENEST.....	72	OXERVATE.....	154
MENOSTAR.....	72	PALYNZIQ.....	155
<i>methamphetamine hcl</i>	33	PANZYGA.....	92
<i>miglustat</i>	121	PEMAZYRE.....	156
<i>modafinil</i>	9	<i>phenobarbital</i>	75
MULPLETA.....	123	PIQRAY (200 MG DAILY DOSE).....	157
MYCAPSSA.....	124	PIQRAY (250 MG DAILY DOSE).....	157
MYFEMBREE.....	125	PIQRAY (300 MG DAILY DOSE).....	157
MYTESI.....	126	POMALYST.....	158
NATPARA.....	127	PRALUENT.....	159
NAYZILAM.....	128	PREMARIN ORAL.....	72
NERLYNX.....	129	PREMPHASE.....	72
NEXAVAR.....	130	PREMPRO.....	72
NEXLETOL.....	131	PREVYMIS.....	160
NEXLIZET.....	132	PRIVIGEN.....	92
NINLARO.....	133	PROLIA.....	161
<i>nitisinone</i>	134	PROMACTA.....	162
NITYR.....	135	<i>promethazine hcl</i>	76
NORDITROPIN FLEXPRO.....	65	QINLOCK.....	163
<i>norethindrone-eth estradiol</i>	72	RAVICTI.....	164
NORTHERA.....	136	REMICADE.....	165
NOURIANZ.....	137	RETEVMO.....	167
NUBEQA.....	138	RETIN-A.....	168
NUCALA.....	139	RETIN-A MICRO.....	168
NUEDEXTA.....	140	RETIN-A MICRO PUMP.....	168
NUPLAZID.....	141	REVLIMID.....	169
NUTROPIN AQ NUSPIN 10.....	65	REZUROCK.....	170
NUTROPIN AQ NUSPIN 20.....	65	RINVOQ.....	171
NUTROPIN AQ NUSPIN 5.....	65	ROZLYTREK.....	172
OALIVA.....	142	RUBRACA.....	173
OCTAGAM.....	92	RUZURGI.....	174
ODOMZO.....	143	RYDAPT.....	175
OFEV.....	144	SAIZEN.....	65
OMNITROPE.....	65	SAIZENPREP.....	65
ONGENTYS.....	145	<i>sapropterin dihydrochloride</i>	176
ONUREG.....	146	SEROSTIM.....	65
OPSUMIT.....	118	SIGNIFOR.....	177
ORALAIR.....	147		

<i>sildenafil citrate</i>	118	TYKERB	209
SIRTURO	178	TYMLOS	210
SKYRIZI	179	UKONIQ	211
SKYRIZI (150 MG DOSE)	179	UPTRAVI ORAL TABLET	118
SKYRIZI PEN	179	UPTRAVI ORAL TABLET THERAPY	
SOMAVERT	180	PACK	118
SPRYCEL ORAL TABLET 100 MG, 140		VALTOCO 10 MG DOSE	212
MG, 20 MG, 50 MG, 70 MG, 80 MG	181	VALTOCO 15 MG DOSE	212
STELARA	182	VALTOCO 20 MG DOSE	212
STIVARGA	184	VALTOCO 5 MG DOSE	212
SUBSYS	204	VENCLEXTA	213
<i>sunitinib malate</i>	185	VENCLEXTA STARTING PACK	213
SUNOSI	186	VENTAVIS	118
SUTENT	187	VERZENIO	214
SYMDEKO	188	VITRAKVI	215
TABRECTA	189	VIZIMPRO	216
<i>tadalafil</i>	190	VOSEVI	217
<i>tadalafil (pah)</i>	118	VOTRIENT	218
TAFINLAR	191	VYNDAMAX	219
TAGRISO	192	VYNDAQEL	220
TAKHZYRO	193	VYVANSE	221
TALTZ	194	WAKIX	222
TALZENNA	195	WELIREG	223
TARGRETIN EXTERNAL	196	XALKORI	224
TASIGNA	197	XCOPRI	225
<i>tazarotene</i>	168	XCOPRI (250 MG DAILY DOSE)	225
TAZORAC	168	XCOPRI (350 MG DAILY DOSE)	225
TAZVERIK	198	XELJANZ ORAL SOLUTION	226
TEGSEDI	199	XELJANZ ORAL TABLET	226
TEPMETKO	200	XELJANZ XR	226
<i>teriparatide (recombinant)</i>	201	XERMELO	227
<i>tetrabenazine</i>	202	XGEVA	228
<i>thioridazine hcl</i>	77	XIFAXAN ORAL TABLET 550 MG	229
TIBSOVO	203	XOLAIR	230
TRACLEER	118	XOSPATA	231
<i>tretinoin external</i>	168	XPOVIO (100 MG ONCE WEEKLY)	232
<i>tretinoin microsphere</i>	168	XPOVIO (40 MG ONCE WEEKLY)	232
<i>trihexyphenidyl hcl</i>	70	XPOVIO (40 MG TWICE WEEKLY)	232
TRIKAFTA	205	XPOVIO (60 MG ONCE WEEKLY)	232
<i>trimipramine maleate</i>	78	XPOVIO (60 MG TWICE WEEKLY)	232
TRUSELTIQ (100MG DAILY DOSE)	206	XPOVIO (80 MG ONCE WEEKLY)	232
TRUSELTIQ (125MG DAILY DOSE)	206	XPOVIO (80 MG TWICE WEEKLY)	232
TRUSELTIQ (50MG DAILY DOSE)	206	XTANDI	233
TRUSELTIQ (75MG DAILY DOSE)	206	XURIDEN	234
TUKYSA	207	YONSA	235
TURALIO	208	ZEJULA	236

ZELBORAF.....	237
ZOLINZA.....	238
ZOMACTON.....	65
ZORBTIVE.....	65
ZYDELIG.....	239
ZYKADIA.....	240